These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21826673)

  • 81. Familial non-medullary thyroid carcinoma: an update.
    Nosé V
    Endocr Pathol; 2008; 19(4):226-40. PubMed ID: 18931957
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The impact of family history on non-medullary thyroid cancer.
    Nixon IJ; Suárez C; Simo R; Sanabria A; Angelos P; Rinaldo A; Rodrigo JP; Kowalski LP; Hartl DM; Hinni ML; Shah JP; Ferlito A
    Eur J Surg Oncol; 2016 Oct; 42(10):1455-63. PubMed ID: 27561845
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Relationship of p53 gene mutation with pathological characteristics and prognosis of thyroid carcinoma].
    Song Y; Wang L; Huang G; Yuan S; Xiao L
    Hua Xi Yi Ke Da Xue Xue Bao; 2000 Sep; 31(3):298-9, 314. PubMed ID: 12545813
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases.
    Park YJ; Ahn HY; Choi HS; Kim KW; Park DJ; Cho BY
    Thyroid; 2012 Apr; 22(4):356-62. PubMed ID: 22280228
    [TBL] [Abstract][Full Text] [Related]  

  • 85. An update on familial nonmedullary thyroid cancer.
    Ammar SA; Alobuia WM; Kebebew E
    Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.
    Miasaki FY; Fuziwara CS; Carvalho GA; Kimura ET
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33218058
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Familial Non-Medullary Thyroid Cancer Represents an Independent Risk Factor for Increased Cancer Aggressiveness: A Retrospective Analysis of 74 Families.
    Tavarelli M; Russo M; Terranova R; Scollo C; Spadaro A; Sapuppo G; Malandrino P; Masucci R; Squatrito S; Pellegriti G
    Front Endocrinol (Lausanne); 2015; 6():117. PubMed ID: 26284028
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Comparison Between Clinicopathological Characteristics,
    Yang T; Huang L; Chen C; Luo H; Jiang Y
    Front Oncol; 2021; 11():616974. PubMed ID: 34926235
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic findings.
    Navas-Carrillo D; Ríos A; Rodríguez JM; Parrilla P; Orenes-Piñero E
    Biochim Biophys Acta; 2014 Dec; 1846(2):468-76. PubMed ID: 25218916
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
    Hińcza K; Kowalik A; Kowalska A
    Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study.
    Robenshtok E; Tzvetov G; Grozinsky-Glasberg S; Shraga-Slutzky I; Weinstein R; Lazar L; Serov S; Singer J; Hirsch D; Shimon I; Benbassat C
    Thyroid; 2011 Jan; 21(1):43-8. PubMed ID: 20954815
    [TBL] [Abstract][Full Text] [Related]  

  • 92. BRAF mutations in acute leukemias.
    Lee JW; Soung YH; Park WS; Kim SY; Nam SW; Min WS; Lee JY; Yoo NJ; Lee SH
    Leukemia; 2004 Jan; 18(1):170-2. PubMed ID: 14603338
    [No Abstract]   [Full Text] [Related]  

  • 93. Familial non-medullary thyroid carcinoma: pathology review in 27 affected cases from 13 French families.
    Leprat F; Bonichon F; Guyot M; Trouette H; Trojani M; Vergnot V; Longy M; Belleannée G; de Mascarel A; Roger P
    Clin Endocrinol (Oxf); 1999 May; 50(5):589-94. PubMed ID: 10468924
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Does familial non-medullary thyroid cancer adversely affect survival?
    Triponez F; Wong M; Sturgeon C; Caron N; Ginzinger DG; Segal MR; Kebebew E; Duh QY; Clark OH
    World J Surg; 2006 May; 30(5):787-93. PubMed ID: 16479341
    [TBL] [Abstract][Full Text] [Related]  

  • 95. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
    Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
    J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [A Familial Non Medullary Thyroid Carcinoma (FNMTC) : a clinical and genetic update].
    Valdes-Socin H; Palmeira L; Burlacu MC; Daly AF; Bours V; Beckers A
    Rev Med Liege; 2016 Dec; 71(12):557-561. PubMed ID: 28387096
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors.
    Cirello V
    Minerva Endocrinol (Torino); 2021 Mar; 46(1):5-20. PubMed ID: 33045820
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Genetic susceptibility to hereditary non-medullary thyroid cancer.
    Kamani T; Charkhchi P; Zahedi A; Akbari MR
    Hered Cancer Clin Pract; 2022 Mar; 20(1):9. PubMed ID: 35255942
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Novel truncating germline variant reinforces
    Oriola J; Díez O; Mora M; Halperin I; Martínez S; Masas M; Tenes A; Bernal A; Duran R; Orois A
    J Med Genet; 2024 Sep; 61(10):939-942. PubMed ID: 39103207
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Ras mutations are uncommon in sporadic thyroid cancer in children and young adults.
    Fenton C; Anderson J; Lukes Y; Dinauer CA; Tuttle RM; Francis GL
    J Endocrinol Invest; 1999 Nov; 22(10):781-9. PubMed ID: 10614528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.